Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Docs reconsider drug-coated stents
Well, maybe drug-coated stents aren't so bad after all. Some doctors are now saying that the medical community overreacted to data on the clotting risks of the eluting stents. New data, plus a closer analysis of the old, is leading cardiologists to consider returning to the drug-coated stents for some patients.
But even if the clotting risks aren't as bad as originally thought, some doctors and researchers still say that only the sickest patients should get stents at all. Diet and drugs--including statins and beta blockers--should come first for most, they say. For high-risk patients, on the other hand, stents work. And drug-coated stents don't appear to be less safe than the bare ones. They are, however, less costly--which may continue to drive sales away.
- read the New York Times report
Related Articles:
Study: Coated stents aren't cost-effective. Report
Little common ground in stent controversy. Report
Tough times for stent market. Report
Congress spotlights J&J stent ops. Report
Decline in drug-coated stent use at cardiac centers. Report
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness


